A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline
-
Enrollment
This study is not currently enrolling. -
Research Area
Neuroscience Research -
Location
-
Principal Investigator
-
Sponsor
Eli Lilly
This study is looking to assess the effect of remternetug versus
placebo on time to clinically meaningful
progression in participants with early AD.